Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24

Showing 24 citing articles:

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 11
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Synthetic Gene Circuits as a Promising Approach in Cancer Immunotherapy
Bhanuprakash Ananthakumar, Nagashri Nanjundeshwara, Archana Lakshmaiah, et al.
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 391-418
Closed Access | Times Cited: 5
Anti-Cancer and Pro-Immune Effects of Lauric Acid on Colorectal Cancer Cells
Shiori Mori, Rina Fujiwara‐Tani, Ruiko Ogata, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 1953-1953
Open Access
Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials
Consolato Sergi, Mervin Burnett, Eugeniu Jantuan, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 664-664
Open Access
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions
Nadia Ghazali, Marina Chiara Garassino, Natasha B. Leighl, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Inflammation and cancer: molecular mechanisms and clinical consequences
Hikmet Akkız, Cem Şimşek, Deniz Balcı, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma
Junjian Shen, Xingxing Wang, Kaifan Yu, et al.
Abdominal Radiology (2025)
Closed Access
Benign non-immune cells in tumor microenvironment
Shaowen Liu, Chunhui Liu, Yuan He, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Role of Mitochondria‐Related Genes in NSCLC: Prognostic Implications and Immune Microenvironment Influence
Zhenye Pu, Bin Liu, Fang Jin, et al.
International Journal of Clinical Practice (2025) Vol. 2025, Iss. 1
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies
Haochuan Guo, Xinru Xu, Jiaxi Zhang, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1048-1048
Open Access | Times Cited: 4
Contemporary Approaches to Immunotherapy of Solid Tumors
A. V. Kuznetsova, Ksenia А. Glukhova, О. П. Попова, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2270-2270
Open Access | Times Cited: 3
Combined KRAS and TP53 mutation in patients with colorectal cancer enhance chemoresistance to promote postoperative recurrence and metastasis
YiMeng Tang, Fan Yao
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
Thomas Enzler, Jiaqi Shi, Jake McGue, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2953-2953
Open Access | Times Cited: 2
Novel KRAS Inhibitors for Treating Non-Small-Cell Lung Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 773-774
Open Access | Times Cited: 1
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1196-1198
Open Access | Times Cited: 1
Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma
Minxiao Yang, Noah Shulkin, Edgar R. Gonzalez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Novel KRAS Inhibitors for Treating Non-small Cell Lung Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1201-1202
Open Access
Integrative multi‐omic and machine learning approach for prognostic stratification and therapeutic targeting in lung squamous cell carcinoma
Xiao Zhang, Pengpeng Zhang, Qianhe Ren, et al.
BioFactors (2024)
Closed Access
Advances in Cancer Treatment and Monitoring: Insights from KRAS Inhibitors and Germline Epitope Burden Monitoring
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 1815-1817
Open Access
A New Frontier in Targeted Therapies: Harnessing PROTACs and Advanced Delivery Systems
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 1818-1820
Open Access
The pan-cancer landscape of crosstalk between leukocyte transendothelial migration-related genes and tumor microenvironment relevant to prognosis and immunotherapy response
Hao Li, Xiaochen Niu, Rui Cheng
Translational Cancer Research (2024) Vol. 13, Iss. 10, pp. 5247-5264
Open Access
A novel regulatory axis of MSI2-AGO2/miR-30a-3p-CGRRF1 drives cancer chemoresistance by upregulating the KRAS/ERK pathway
Runhui Lu, Ying Zhang, Ran Chen, et al.
Neoplasia (2024) Vol. 59, pp. 101082-101082
Closed Access
Targeting Cancer: A New Era in Cancer Therapy through Immune Fitness Modulation and KRAS Degradation
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 12, pp. 2074-2076
Open Access
Page 1

Scroll to top